Nasal administration of a fully human anti-CD3 monoclonal antibody modulates T cell inflammatory responses in COVID-19
news-medical.net,
Researchers assessed the impact of an anti-CD3 monoclonal antibody called Foralumab in COVID-19 treatment.
Researchers assessed the impact of an anti-CD3 monoclonal antibody called Foralumab in COVID-19 treatment.
A pilot trial by investigators from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare…
A pilot trial by investigators from Brigham and Women’s Hospital, a founding member of the Mass General Brigham health care…
In a pilot trial and clinical sample-based investigations, the drug Foralumab decreased inflammatory markers in patients with…